Cargando…

Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis

OBJECTIVES: Cardiac magnetic resonance (CMR) was used to investigate the extracellular compartment and myocardial fibrosis in patients with aortic stenosis, as well as their association with other measures of left ventricular decompensation and mortality. BACKGROUND: Progressive myocardial fibrosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Chin, Calvin W.L., Everett, Russell J., Kwiecinski, Jacek, Vesey, Alex T., Yeung, Emily, Esson, Gavin, Jenkins, William, Koo, Maria, Mirsadraee, Saeed, White, Audrey C., Japp, Alan G., Prasad, Sanjay K., Semple, Scott, Newby, David E., Dweck, Marc R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683736/
https://www.ncbi.nlm.nih.gov/pubmed/28017384
http://dx.doi.org/10.1016/j.jcmg.2016.10.007
_version_ 1783278346252058624
author Chin, Calvin W.L.
Everett, Russell J.
Kwiecinski, Jacek
Vesey, Alex T.
Yeung, Emily
Esson, Gavin
Jenkins, William
Koo, Maria
Mirsadraee, Saeed
White, Audrey C.
Japp, Alan G.
Prasad, Sanjay K.
Semple, Scott
Newby, David E.
Dweck, Marc R.
author_facet Chin, Calvin W.L.
Everett, Russell J.
Kwiecinski, Jacek
Vesey, Alex T.
Yeung, Emily
Esson, Gavin
Jenkins, William
Koo, Maria
Mirsadraee, Saeed
White, Audrey C.
Japp, Alan G.
Prasad, Sanjay K.
Semple, Scott
Newby, David E.
Dweck, Marc R.
author_sort Chin, Calvin W.L.
collection PubMed
description OBJECTIVES: Cardiac magnetic resonance (CMR) was used to investigate the extracellular compartment and myocardial fibrosis in patients with aortic stenosis, as well as their association with other measures of left ventricular decompensation and mortality. BACKGROUND: Progressive myocardial fibrosis drives the transition from hypertrophy to heart failure in aortic stenosis. Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis. METHODS: In a prospective observational cohort study, 203 subjects (166 with aortic stenosis [69 years; 69% male]; 37 healthy volunteers [68 years; 65% male]) underwent comprehensive phenotypic characterization with clinical imaging and biomarker evaluation. On CMR, we quantified the total extracellular volume of the myocardium indexed to body surface area (iECV). The iECV upper limit of normal from the control group (22.5 ml/m(2)) was used to define extracellular compartment expansion. Areas of replacement mid-wall LGE were also identified. All-cause mortality was determined during 2.9 ± 0.8 years of follow up. RESULTS: iECV demonstrated a good correlation with diffuse histological fibrosis on myocardial biopsies (r = 0.87; p < 0.001; n = 11) and was increased in patients with aortic stenosis (23.6 ± 7.2 ml/m(2) vs. 16.1 ± 3.2 ml/m(2) in control subjects; p < 0.001). iECV was used together with LGE to categorize patients with normal myocardium (iECV <22.5 ml/m(2); 51% of patients), extracellular expansion (iECV ≥22.5 ml/m(2); 22%), and replacement fibrosis (presence of mid-wall LGE, 27%). There was evidence of increasing hypertrophy, myocardial injury, diastolic dysfunction, and longitudinal systolic dysfunction consistent with progressive left ventricular decompensation (all p < 0.05) across these groups. Moreover, this categorization was of prognostic value with stepwise increases in unadjusted all-cause mortality (8 deaths/1,000 patient-years vs. 36 deaths/1,000 patient-years vs. 71 deaths/1,000 patient-years, respectively; p = 0.009). CONCLUSIONS: CMR detects ventricular decompensation in aortic stenosis through the identification of myocardial extracellular expansion and replacement fibrosis. This holds major promise in tracking myocardial health in valve disease and for optimizing the timing of valve replacement. (The Role of Myocardial Fibrosis in Patients With Aortic Stenosis; NCT01755936)
format Online
Article
Text
id pubmed-5683736
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-56837362017-11-20 Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis Chin, Calvin W.L. Everett, Russell J. Kwiecinski, Jacek Vesey, Alex T. Yeung, Emily Esson, Gavin Jenkins, William Koo, Maria Mirsadraee, Saeed White, Audrey C. Japp, Alan G. Prasad, Sanjay K. Semple, Scott Newby, David E. Dweck, Marc R. JACC Cardiovasc Imaging Article OBJECTIVES: Cardiac magnetic resonance (CMR) was used to investigate the extracellular compartment and myocardial fibrosis in patients with aortic stenosis, as well as their association with other measures of left ventricular decompensation and mortality. BACKGROUND: Progressive myocardial fibrosis drives the transition from hypertrophy to heart failure in aortic stenosis. Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis. METHODS: In a prospective observational cohort study, 203 subjects (166 with aortic stenosis [69 years; 69% male]; 37 healthy volunteers [68 years; 65% male]) underwent comprehensive phenotypic characterization with clinical imaging and biomarker evaluation. On CMR, we quantified the total extracellular volume of the myocardium indexed to body surface area (iECV). The iECV upper limit of normal from the control group (22.5 ml/m(2)) was used to define extracellular compartment expansion. Areas of replacement mid-wall LGE were also identified. All-cause mortality was determined during 2.9 ± 0.8 years of follow up. RESULTS: iECV demonstrated a good correlation with diffuse histological fibrosis on myocardial biopsies (r = 0.87; p < 0.001; n = 11) and was increased in patients with aortic stenosis (23.6 ± 7.2 ml/m(2) vs. 16.1 ± 3.2 ml/m(2) in control subjects; p < 0.001). iECV was used together with LGE to categorize patients with normal myocardium (iECV <22.5 ml/m(2); 51% of patients), extracellular expansion (iECV ≥22.5 ml/m(2); 22%), and replacement fibrosis (presence of mid-wall LGE, 27%). There was evidence of increasing hypertrophy, myocardial injury, diastolic dysfunction, and longitudinal systolic dysfunction consistent with progressive left ventricular decompensation (all p < 0.05) across these groups. Moreover, this categorization was of prognostic value with stepwise increases in unadjusted all-cause mortality (8 deaths/1,000 patient-years vs. 36 deaths/1,000 patient-years vs. 71 deaths/1,000 patient-years, respectively; p = 0.009). CONCLUSIONS: CMR detects ventricular decompensation in aortic stenosis through the identification of myocardial extracellular expansion and replacement fibrosis. This holds major promise in tracking myocardial health in valve disease and for optimizing the timing of valve replacement. (The Role of Myocardial Fibrosis in Patients With Aortic Stenosis; NCT01755936) Elsevier 2017-11 /pmc/articles/PMC5683736/ /pubmed/28017384 http://dx.doi.org/10.1016/j.jcmg.2016.10.007 Text en © 2017 Elsevier Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chin, Calvin W.L.
Everett, Russell J.
Kwiecinski, Jacek
Vesey, Alex T.
Yeung, Emily
Esson, Gavin
Jenkins, William
Koo, Maria
Mirsadraee, Saeed
White, Audrey C.
Japp, Alan G.
Prasad, Sanjay K.
Semple, Scott
Newby, David E.
Dweck, Marc R.
Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis
title Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis
title_full Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis
title_fullStr Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis
title_full_unstemmed Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis
title_short Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis
title_sort myocardial fibrosis and cardiac decompensation in aortic stenosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683736/
https://www.ncbi.nlm.nih.gov/pubmed/28017384
http://dx.doi.org/10.1016/j.jcmg.2016.10.007
work_keys_str_mv AT chincalvinwl myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT everettrussellj myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT kwiecinskijacek myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT veseyalext myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT yeungemily myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT essongavin myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT jenkinswilliam myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT koomaria myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT mirsadraeesaeed myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT whiteaudreyc myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT jappalang myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT prasadsanjayk myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT semplescott myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT newbydavide myocardialfibrosisandcardiacdecompensationinaorticstenosis
AT dweckmarcr myocardialfibrosisandcardiacdecompensationinaorticstenosis